BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 24751701)

  • 1. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
    J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
    Leblanc E; Gauthier H; Querleu D; Ferron G; Zerdoud S; Morice P; Uzan C; Lumbroso S; Lecuru F; Bats AS; Ghazzar N; Bannier M; Houvenaeghel G; Brenot-Rossi I; Narducci F
    Ann Surg Oncol; 2011 Aug; 18(8):2302-9. PubMed ID: 21347790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients.
    Cervino AR; Pomerri F; Alfieri R; Sileni VC; Castoro C; Galuppo S; Evangelista L
    Nucl Med Commun; 2014 Feb; 35(2):160-8. PubMed ID: 24220054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
    Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
    Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.
    Picchio M; Mangili G; Samanes Gajate AM; De Marzi P; Spinapolice EG; Mapelli P; Giovacchini G; Sigismondi C; Viganò R; Sironi S; Messa C
    Nucl Med Commun; 2010 Jun; 31(6):506-12. PubMed ID: 20168262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
    Flamen P; Lerut A; Van Cutsem E; Cambier JP; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
    Kim SJ; Koo PJ; Chang S
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):723-31. PubMed ID: 26891957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study.
    McDonough PB; Jones DR; Shen KR; Northup PG; Galysh RL; Hernandez A; White GE; Kahaleh M; Shami VM
    Am J Gastroenterol; 2008 Mar; 103(3):570-4. PubMed ID: 17941963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
    Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.